AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39040670
Drug: Celsior® solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celsior® solution
Trial: 39040670
Drug: St Thomas®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St Thomas® solution
Trial: 39041411
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 6 months with salvage radiotherapy (SRT)
Trial: 39041411
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 24 months with salvage radiotherapy (SRT)
Trial: 39041887
Drug: Vaccine (Flublok;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (Flublok; Sanofi Pasteur)
Trial: 39041933
Drug: Increased differential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased differential stroke volume (greater than 30 mL)
Trial: 39041933
Drug: Balanced differential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced differential stroke volume (greater than or equal to -30 mL to ≤30 mL)
Trial: 39041933
Drug: Negative differential
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative differential stroke volume (less than -30 mL)
Trial: 39042292
Drug: CT-P41 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P41 (60 mg subcutaneous)
Trial: 39042407
Drug: ZY5301 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY5301 300 mg/d
Trial: 39042407
Drug: ZY5301 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY5301 600 mg/d
Trial: 39042875
Drug: Algorithm designed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Algorithm designed to guide the deprescribing of drugs for OAB
Trial: 39043009
Drug: Durvalumab 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 10 mg/kg plus Tremelimumab 3 mg/kg
Trial: 39043009
Drug: Durvalumab 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg
Trial: 39043009
Drug: Durvalumab 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Trial: 39043009
Drug: Durvalumab 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 10 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Trial: 39043009
Drug: All dose-expansion
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dose-expansion cohorts
Trial: 39043146
Drug: FYTF-919 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FYTF-919 (100 mL per day, oral)
Trial: 39043348
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during sleep restriction
Trial: 39043348
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during recovery sleep
Trial: 39043513
Drug: StrataGraft treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: StrataGraft treatment
Trial: 39043593
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy plus health education (intervention group, n=20)
Trial: 39043650
Drug: 20 min
RxNorm normalized name: wheat germ oil 20 minim ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 min daily HVBR (fast breathing with long breath holds) for 3 weeks
Trial: 39043915
Drug: Milk supplementation
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplementation (390 ml daily)
Trial: 39044381
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (10 mg/kg once) with fluconazole
Trial: 39044861
Drug: Vaccine adverse
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine adverse effects after dose one
Trial: 39045544
Drug: Toripalimab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (240 mg) every 3 weeks plus nab-paclitaxel weekly for 12 weeks after four cycles of epirubicin-cyclophosphamide every 2 weeks
Trial: 39045795
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) for PTSD
Trial: 39602624
Drug: Subcutaneous lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lenacapavir every 26 weeks
Trial: 39046157
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral emtricitabine-tenofovir alafenamide (F/TAF)
Trial: 39046157
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control)
Trial: 39046314
Drug: Intra-articular hip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hip injection with prior subcutaneous LA (2 mL of lidocaine 1%)
Trial: 39046314
Drug: Intra-articular hip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hip injection without prior subcutaneous LA
Trial: 39046314
Drug: Intra-articular hip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hip injection with prior subcutaneous LA
Trial: 39046333
Drug: Concomitant inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant inhibitors or inducers of cytochrome P450 3A4 and/or P-glycoprotein
Trial: 39046647
Drug: Sanjie Analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanjie Analgesic Capsule (SAC) 1.6 g 3 times per day for 3 menstrual cycles
Trial: 39046647
Drug: Placebo 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.6 g 3 times per day for 3 menstrual cycles
Trial: 39046695
Drug: LAMA +
RxNorm normalized name: Lama palagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAMA + long-acting β agonist
Trial: 39046695
Drug: Other inhaler
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other inhaler treatments
Trial: 39046695
Drug: Inhaler treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler treatment (general)
Trial: 39046741
Drug: Early intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention group (pharmacist-led OAC prescription)
Trial: 39046767
Drug: Ruxolitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (10 mg twice daily for ages ≥12 to <18 years; 5 mg twice daily for ages ≥6 to <12 years; 4 mg/m2 twice daily for ages ≥2 to <6 years)
Trial: 39047219
Drug: Extended letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended letrozole therapy (ELT)
Trial: 39047868
Drug: Creatine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (20 g/day for 7 days)
Trial: 39048608
Drug: Clesacostat (PF-05221304),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clesacostat (PF-05221304), an acetyl coA carboxylase inhibitor (ACCi), 25 mg dosage.
Trial: 39048701
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + Manual Therapy (ETManual therapy)
Trial: 39048932
Drug: POINCARE-2 strategy
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POINCARE-2 strategy (daily weighing and administration of treatments)
Trial: 39048933
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise programme in primary care (aerobic and strengthening exercises, twice a week for 12 weeks, daily walks)
Trial: 39048933
Drug: Unsupervised home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised home-based exercise (daily walks and sit-to-stand exercise)
Trial: 39049019
Drug: Sequential 4-channel
RxNorm normalized name: CHANNEL CATFISH
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential 4-channel neuromuscular electrical stimulation (NMES)
Trial: 39049042
Drug: Biomarkers investigated
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarkers investigated (neuropsychological tests: MMSE and delayed free recall, brain glucose metabolism)
Trial: 39049073
Drug: Orlistat (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (360 mg/day)
Trial: 39049087
Drug: Incretin effect
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incretin effect measured as the difference between plasma insulin area under the curve during an oral glucose tolerance test (OGTT) and intravenous glucose infusion.
Trial: 39049187
Drug: Water-filtered infrared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-filtered infrared A radiation (WIRA) whole-body hyperthermia combined with immune checkpoint inhibitor (ICI) therapy (tislelizumab)
Trial: 39049618
Drug: Friction mechanics
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friction mechanics using elastomeric chain (160 g/side)
Trial: 39049802
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment with saline infusion
Trial: 39049802
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment with exendin(9-39)NH2 infusion
Trial: 39052242
Drug: Bintrafusp alfa,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa, 1200 mg, intravenously once every 2 weeks
Trial: 39052256
Drug: Atezolizumab, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab, 1200 mg intravenously, administered on day 1 of each 21-day cycle for four cycles, followed by chemoradiation therapy (CRT)
Trial: 39052256
Drug: Atezolizumab, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab, 1200 mg every 21 days continued for 1 year after CRT
Trial: 39052256
Drug: Atezolizumab, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab, 1200 mg, as part of the treatment regimen
Trial: 39052256
Drug: Atezolizumab treatment
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab treatment
Trial: 39052716
Drug: RSM01, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSM01, an investigational anti-RSV prefusion F monoclonal antibody (mAb); details on dosage and duration not available.
Trial: 39052715
Drug: 3-day azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day azithromycin treatment
Trial: 39052715
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment (control)
Trial: 39052893
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) surgery with audible ECochG monitoring
Trial: 39052893
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) surgery without audible ECochG monitoring
Trial: 39053611
Drug: Deuruxolitinib 8
RxNorm normalized name: Deuruxolitinib
DrugBank: Deuruxolitinib (DB18847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuruxolitinib 8 mg twice daily
Trial: 39053611
Drug: Deuruxolitinib 12
RxNorm normalized name: Deuruxolitinib
DrugBank: Deuruxolitinib (DB18847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuruxolitinib 12 mg twice daily
Trial: 39053878
Drug: Subcrestal ≈2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcrestal ≈2 mm implants with LA
Trial: 39053878
Drug: Subcrestal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcrestal implants
Trial: 39053948
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg plus background csDMARD(s)
Trial: 39053954
Drug: Allopurinol (200-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (200-500 mg daily)
Trial: 39053957
Drug: BETTER Women
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BETTER Women programme with a trained peer health coach providing ongoing support after receipt of a BETTER prevention prescription.
Trial: 39053960
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg AMK injection on the first and fourth day of treatment
Trial: 39053961
Drug: Early pharmacotherapeutic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early pharmacotherapeutic treatment of clinically symptomatic and echocardiography-confirmed haemodynamically significant PDA
Trial: 39054420
Drug: Renin-Angiotensin-System (RAS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-Angiotensin-System (RAS) blockers with beta-blockers and optionally spironolactone
Trial: 39054460
Drug: Irreversible Electroporation
RxNorm normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irreversible Electroporation (IRE) followed by reduced dose MR guided Radiation Therapy (MRgRT) with either 32.5 Gy in 5 Fractions or 22 Gy in 2 fractions
Trial: 39054462
Drug: E + P + C (epacadostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + P + C (epacadostat 100 mg BID + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Trial: 39054462
Drug: PBO + P + C (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO + P + C (placebo + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Trial: 39054476
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 21 days plus oral epacadostat 100 mg twice daily (combination)
Trial: 39054485
Drug: Epacadostat 100
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat 100 mg BID plus pembrolizumab
Trial: 39054514
Drug: Exercise combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise combined with Manual Therapy (MT)
Trial: 39054770
Drug: (2R,6R)-Hydroxynorketamine (RR-HNK)
RxNorm normalized name: Zithranol-RR
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2R,6R)-Hydroxynorketamine (RR-HNK) at doses of 0.1-4 mg/kg (SAD) and 1-2 mg/kg (MAD) administered via IV over 40 minutes
Trial: 39055379
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) therapy
Trial: 39055495
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of utidelone and capecitabine
Trial: 39055663
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral β-blocker therapy
Trial: 39055663
Drug: No β-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No β-blocker therapy (Control)
Trial: 39055703
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (2DR) - dolutegravir or darunavir/cobicistat + lamivudine
Trial: 39055703
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen (3DR) - integrase inhibitor-based
Trial: 39056160
Drug: IGU monotherapy
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IGU monotherapy (25 mg twice daily)
Trial: 39056160
Drug: IGU +
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IGU + MTX (10-15 mg weekly for MTX and 25 mg twice daily for IGU)
Trial: 39056160
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX monotherapy (10-15 mg weekly)
Trial: 39056160
Drug: IGU monotherapy
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IGU monotherapy
Trial: 39056338
Drug: AZD3427 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3427 (5, 15, or 45 mg)
Trial: 39056338
Drug: AZD3427 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3427 (subcutaneous injection)
Trial: 39056349
Drug: Aficamten (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten (5-20 mg)
Trial: 39057291
Drug: Second-line axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-line axitinib treatment
Trial: 39058022
Drug: Cipargamin (intravenous)
RxNorm normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin (intravenous)
Trial: 39058662
Drug: QPOP-guided chemotherapy
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QPOP-guided chemotherapy
Trial: 39058740
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin A (BoNT-A) injection into calf muscles
Trial: 39058740
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline injection into calf muscles (placebo)
Trial: 39058951
Drug: Copanlisib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine)
Trial: 39058966
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) added to multidrug chemotherapy
Trial: 39059184
Drug: CDK4/6 inhibitor
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitor (CDK4/6i) therapy
Trial: 39059184
Drug: Letrozole (upfront
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (upfront therapy)
Trial: 39059373
Drug: Sildenafil cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil cream, 3.6%
Trial: 39059389
Drug: Longitudinal cfEBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal cfEBV DNA tracking during neoadjuvant chemotherapy and radiotherapy
Trial: 39059398
Drug: Foritinib (80,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foritinib (80, 120, 160, or 210 mg orally once daily over 21-day cycles in phase 2a; 160 mg in phase 2b)
Trial: 39059398
Drug: Foritinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foritinib (160 mg orally once daily in phase 2b)
Trial: 39059407
Drug: BIIB078 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB078 (5 mg, 10 mg, 20 mg, 35 mg, 60 mg, or 90 mg)
Trial: 39059407
Drug: BIIB078 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB078 (any dose)
Trial: 39060022
Drug: TG6050 (oncolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG6050 (oncolytic vaccinia virus encoding hIL-12 and anti-CTLA-4 antibody)
Trial: 39060370
Drug: AB002 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB002 1.5 µg/kg
Trial: 39060370
Drug: AB002 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB002 3 µg/kg
Trial: 39060374
Drug: CI-8993 (fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-8993 (fully human IgG1κ monoclonal antibody)
Trial: 39060961
Drug: Consolidation doublet
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long-course chemoradiation (LCRT)
Trial: 39060961
Drug: Consolidation triplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long-course chemoradiation (LCRT)
Trial: 39060961
Drug: Neoadjuvant long-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant long-course chemoradiation (LCRT) followed by consolidation chemotherapy
Trial: 39061093
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist, liraglutide
Trial: 39061599
Drug: Maternal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal blood biomarker test for spontaneous preterm birth risk screening followed by preventive treatments for those screening positive.
Trial: 39062003
Drug: STP1 (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STP1 (combination of ibudilast and bumetanide)
Trial: 39065260
Drug: TAK-426 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-426 (10 µg)
Trial: 39065260
Drug: TAK-426 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-426 (2 µg and 5 µg)
Trial: 39066382
Drug: Priorix vaccine
RxNorm normalized name: PRIORIX vaccine 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priorix vaccine (GlaxoSmithKline Biologicals)